Entrada Therapeutics, Inc.
NASDAQEntrada Therapeutics heads into its May 8 earnings event carrying a story that goes well beyond the financials — topline data from its lead DMD programme drops on May 7, the day before the print. The company announced late on May 6 that it will release Cohort 1 results from the Phase 1/2 ELEVATE-44-201 study of ENTR-601-44, its exon-44 skipping candidate for Duchenne Muscular…
Snapshot as of 7 May 2026
Entrada Therapeutics heads into its May 8 earnings event carrying a story that goes well beyond the financials — topline data from its lead DMD programme drops on May 7, the day before the print. The company announced…
Entrada Therapeutics enters May 7 — when it releases topline Phase 1/2 data for its lead Duchenne Muscular Dystrophy program — having already gained 22% on the week and with its own executives reducing positions into…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRDA — free to start on ORTEX.
Sign up for free →Open TRDA on ORTEX